Holen Sie sich die Stockscreener-App
8.21
1.91%
-0.16
Handel nachbörslich:
8.21
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower Than Expected Loss Reflects Operational DisciplineAI Trading Community - Newser
Upstream Bio (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue; Stock Edges LowerForward EPS Estimate - Newser
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Number of shareholders of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target - TipRanks
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference - Sahm
Upstream Bio (UPB) Reveals Promising Phase 2 Trial Results for V - GuruFocus
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026 - Traders Union
Upstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma - Quiver Quantitative
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial - GlobeNewswire
New sinus and asthma drug trial slashes steroid use, sinus surgery by 83% - Stock Titan
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates - MSN
Upstream Bio (UPB) Surges +3.41%, Nearing $9.54 Resistance 2026-05-17Market Analysis - newser.com
MSN Money - MSN
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
UPB Maintains Rating by Mizuho -- Price Target Lowered to $50.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB) - The Globe and Mail
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $42 to $43 - Moomoo
Mizuho lowers Upstream Bio stock price target on operating spend tweaks - Investing.com Canada
Mizuho Adjusts Price Target on Upstream Bio to $50 From $51, Maintains Outperform Rating - Moomoo
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - Sahm
Upstream Bio, Inc. (UPB) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Upstream Bio : Corporate Presentation May 2026 (May 13, 2026) - marketscreener.com
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for major respiratory diseases - TradingView
Upstream Bio, Inc. 2026 Q1 Financials and Risk Factors – Nasdaq Global Select Market Filing - Minichart
Upstream Bio Reports Q1 2026 Results and Advances Verekitug Toward Phase 3 Trials for Severe Asthma, CRSwNP, and COPD - Minichart
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Upstream Bio, Inc. 1Q 2026: Revenue $1.03M, EPS $(0.75) — 10-Q Summary - TradingView
Upstream Bio reports Q1 2026 net loss $40.6M; cash and short-term investments $294.6M - TradingView
Upstream Bio, Inc. (UPB) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
Upstream Bio, Inc. $UPB Shares Bought by UBS Group AG - MarketBeat
Jennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPB - MarketBeat
773,148 Shares in Upstream Bio, Inc. $UPB Acquired by Pictet Asset Management Holding SA - MarketBeat
Upstream Bio Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
Should I buy Upstream Bio, Inc. (UPB) - Zacks Investment Research
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
UPB Forecast, Price Target & Analyst Ratings | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Segment Overview and Major Growth Areas in the Upstream Bioprocessing Market - openPR.com
Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Upstream Bio (UPB) Stock Bonus Issue (Bearish Sentiment) 2026-04-20Put Flow Alert - Newser
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):